Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, recently announced that its President and Chief Executive Officer, Christopher J. Schaber, PhD, is to deliver a corporate presentation at the 2017 Biotech & Money Inv€$tival Showcase in London, England on Tuesday, November 14 at 1:30 PM GMT. The event will take place at The Waldorf Hilton Hotel.
Biotech and Money connects corporates to capital, and the Inv€$tival Showcase is the most direct way of showcasing the latest investable private and public life science opportunities to their growing investor network, and that of their partners, Jefferies LLC. The four track Inv€$tival Showcase is designed to highlight the latest innovative companies who are looking to raise capital and their profile amongst investors, and provide an opportunity for 1-2-1 investor and B2B meetings in a unique setting, as part of the week of the Jefferies Global Healthcare conference in London. The four tracks are split into industry sub-sectors, with sections for companies working within the fields of immuno-oncology, cell and gene therapy, precision medicine, neuroscience, orphan drugs, digital health and medical devices, as well as an agnostic section for other industry sub-sectors.
Soligenix is currently developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, their first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention and treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn’s disease (SGX203) and acute radiation enteritis (SGX201).
For more information regarding Soligenix, Inc., please visit their website.
Categories: COMPANIES, MEMBER NEWS, NEWS, Soligenix